Delayed recovery associated with persistent serum concentrations after clozapine overdose

Journal of Emergency Medicine

Volumn 25, Issue 1, 2003, Pages 61-66

  Thomas, Lyle ^a   Pollak, P Timothy ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Clozapine; Overdose; Pharmacokinetics; Safety; Therapeutics

Indexed keywords

ACTIVATED CARBON; CLONAZEPAM; CLOZAPINE; FLUPENTIXOL; LORAZEPAM; NEUROLEPTIC AGENT; VALPROIC ACID;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONVALESCENCE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MONITORING; DRUG OVERDOSE; FEMALE; GLASGOW COMA SCALE; HEART VENTRICLE TACHYCARDIA; HUMAN; INTENSIVE CARE UNIT; MEDICAL EXAMINATION; NEUROLOGIC EXAMINATION; PALLIATIVE THERAPY; PREDICTION; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SOMNOLENCE; TREATMENT OUTCOME;

EID: 0038307976     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0736-4679(03)00130-6     Document Type: Article

References (26)

1. Richelson E. Receptor pharmacology of neuroleptics relation to clinical effects . J Clin Psychiatry. 10:1999;5-14.
2. Kinon B.J., Lieberman J.A. Mechanisms of action of atypical antipsychotic drugs a critical analysis . Psychopharmacology (Berl). 124:1996;2-34.
3. Nightingale S.L. From the Food and Drug Administration. JAMA. 263:1990;202.
4. Alvir J.M., Lieberman J.A., Safferman A.Z., Schwimmer J.L., Schaaf J.A. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 329:1993;162-167.
5. Alphs L.D., Anand R. Clozapine the commitment to patient safety . J Clin Psychiatry. 12:1999;39-42.
6. Markowitz J.S., Brown C.S., Moore T.R. Atypical antipsychotics. Part I Pharmacology, pharmacokinetics, and efficacy . Ann Pharmacother. 33:1999;73-85.
7. Burns M.J. The pharmacology and toxicology of atypical antipsychotic agents. J Toxicol Clin Toxicol. 39:2001;1-14.
8. Baldessarini R.J., Frankenburg F.R. Clozapine. A novel antipsychotic agent. N Engl J Med. 324:1991;746-754.
9. Welber M.R., Nevins S. Clozapine overdose, a case report. J Emerg Med. 13:1995;199-202.
10. Le Blaye I., Donatini B., Hall M., Krupp P. Acute overdosage with clozapine a review of the available clinical experience . Pharm Med. 6:1992;169-178.
11. Pollak P.T., Zbuk K. Quetiapine fumarate overdose clinical and pharmacokinetic lessons from extreme conditions . Clin Pharmacol Ther. 68:2000;92-97.
12. Hagg S., Spigset O., Edwardsson H., Bjork H. Prolonged sedation and slowly decreasing clozapine serum concentrations after an overdose. J Clin Psychopharmacol. 19:1999;282-284. [letter].
13. Renwick A.C., Renwick A.G., Flanagan R.J., Ferner R.E. Monitoring of clozapine and norclozapine plasma concentration-time curves in acute overdose. J Toxicol Clin Toxicol. 38:2000;325-328.
14. Reith D., Monteleone J.P., Whyte I.M., Ebelling W., Holford N.H., Carter G.L. Features and toxicokinetics of clozapine in overdose. Ther Drug Monit. 20:1998;92-97.
15. Friedberg R.C., Spyker D.A., Herold D.A. Massive overdoses with sustained-release lithium carbonate preparations pharmacokinetic model based on two case studies . Clin Chem. 37:1991;1205-1209.
16. Vale J.A. Position statement gastric lavage. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists . J Toxicol Clin Toxicol. 35:1997;711-719.
17. Meeker J.E., Herrmann P.W., Som C.W., Reynolds P.C. Clozapine tissue concentrations following an apparent suicidal overdose of Clozaril. J Anal Toxicol. 16:1992;54-56.
18. Roy D.M., Cutten A.E. Clozapine overdose with pronounced neutrophilia a case report . Aust N Z J Psychiatry. 27:1993;530-531. [letter].
19. Broich K., Heinrich S., Marneros A. Acute clozapine overdose plasma concentration and outcome . Pharmacopsychiatry. 31:1998;149-151.
20. Editorial Staff. Clozapine (Management). In: Waksman J, Hurlbut K, Rumack B, eds. POISINDEX ®System. Greenwood Village, CO: MICROMEDEX; Edition Expires 9/2002.
21. Bond G.R. The role of activated charcoal and gastric emptying in gastrointestinal decontamination a state-of-the-art review . Ann Emerg Med. 39:2002;273-286.
22. Chyka P.A. Multiple-dose activated charcoal and enhancement of systemic drug clearance summary of studies in animals and human volunteers . J Toxicol Clin Toxicol. 33:1995;399-405.
23. Minton N.A., Henry J.A. Prevention of drug absorption in simulated theophylline overdose. J Toxicol Clin Toxicol. 33:1995;43-49.
24. Tenenbein M. Position statement whole bowel irrigation. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists . J Toxicol Clin Toxicol. 35:1997;753-762.
25. Burkhart K.K., Wuerz R.C., Donovan J.W. Whole-bowel irrigation as adjunctive treatment for sustained-release theophylline overdose. Ann Emerg Med. 21:1992;1316-1320.
26. Lapatto-Reiniluoto O., Kivisto K.T., Neuvonen P.J. Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs. Clin Pharmacol Ther. 70:2001;255-260.